Amicus Therapeutics Acquisition Advances as Regulatory Reviews Draw Investor Focus

Amicus Therapeutics shareholders have approved the acquisition by BioMarin Pharmaceutical, pending remaining regulatory reviews. The deal's closing is expected following completion of these final approvals, subject to customary conditions. The combination with BioMarin could reshape Amicus Therapeutics' rare disease portfolio and pipeline development. Investors will focus on closing progress, deal milestones, and the combined rare disease business impact on patients, employees, and future product development.